for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cidara Therapeutics Inc

CDTX.OQ

Latest Trade

2.66USD

Change

0.01(+0.38%)

Volume

429

Today's Range

2.66

 - 

2.66

52 Week Range

1.24

 - 

3.29

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.65
Open
2.66
Volume
429
3M AVG Volume
3.71
Today's High
2.66
Today's Low
2.66
52 Week High
3.29
52 Week Low
1.24
Shares Out (MIL)
33.04
Market Cap (MIL)
88.88
Forward P/E
-2.01
Dividend (Yield %)
--

Latest Developments

More

Cidara Reports Qtrly Earnings Per Share $0.08

Mundipharma AG Reports 15.2% Passive Stake In Cidara Therapeutics

Cidara Therapeutics Says Rezafungin Achieved Positive Topline Results In Its Phase 2 Strive B Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cidara Therapeutics Inc

Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.

Industry

Biotechnology & Drugs

Contact Info

6310 Nancy Ridge Dr Ste 101

+1.858.7526170

http://www.cidara.com/

Executive Leadership

Jeffrey L. Stein

President, Chief Executive Officer, Principal Financial Officer, Director

James E. Levine

Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

Paul Daruwala

Chief Operating Officer

Carmen Betancourt

Senior Vice President - Regulatory affairs and quality

Laura A. Navalta

Senior Vice President - Clinical Operations

Key Stats

1.43 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-3.320

2017

-3.180

2018

-2.760

2019(E)

-1.340
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.65
Price To Book (MRQ)
1.81
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
20.34
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-60.93
Return on Equity (TTM)
-45.17

Latest News

Latest News

BRIEF-Cidara Announces Stock And Warrants Offering Worth $120 Mln

* CIDARA THERAPEUTICS ANNOUNCES OFFERING OF COMMON STOCK AND WARRANTS

BRIEF-Cidara Says Additional Data Confirm Positive Results In Antifungal Rezafungin

* CIDARA THERAPEUTICS PROVIDES CLINICAL DATA UPDATES FOR ITS LEAD ANTIFUNGAL REZAFUNGIN

BRIEF-Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin

* CIDARA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 STRIVE TRIAL OF LEAD ANTIFUNGAL REZAFUNGIN

BRIEF-Cidara Posts Q4 Loss Per Share $0.69​

* CIDARA PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Cidara Therapeutics Completes Enrollment in Phase 2 Strive Trial for Antifungal Rezafungin

* CIDARA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 STRIVE TRIAL EVALUATING NOVEL ANTIFUNGAL REZAFUNGIN (CD101 IV) IN INVASIVE FUNGAL INFECTIONS Source text for Eikon: Further company coverage:

BRIEF-Cidara Therapeutics announces pricing of $20 mln private placement

* Cidara Therapeutics announces pricing of $20 million private placement of common stock

BRIEF-Cidara Q2 net loss per share $0.99​

* Cidara provides corporate update and reports second quarter 2017 financial results

BRIEF-Cidara Therapeutics updates on results from studies investigating antifungal CD101

* Cidara therapeutics inc - announces publication of results from in vivo study investigating novel antifungal CD101 in intra-abdominal candidiasis (IAC)

BRIEF-Broadfin Capital reports 5.28 percent passive stake in Cidara Therapeutics as of July 7

* Broadfin Capital LLC reports a 5.28 percent passive stake in Cidara Therapeutics Inc as of July 7, 2017 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Prosight Management LP reports 5.2 pct passive stake in Cidara Therapeutics - SEC filing

* Prosight Management LP reports a 5.2 percent passive stake in Cidara Therapeutics Inc as of June 7, 2017 - SEC filing Source text - (http://bit.ly/2rEN8RH) Further company coverage:

BRIEF-Cidara Therapeutics Q1 loss per share $0.80

* Q1 loss per share $0.80 Source text: (http://bit.ly/2qtarSr) Further company coverage:

BRIEF-Cidara Therapeutics qtrly net loss per share $0.88

* Cidara therapeutics inc - qtrly basic and diluted net loss per share $0.88

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up